What Is 7-Hydroxymitragynine (7OH)? The Complete Guide for Canada (2026)

7-Hydroxymitragynine, commonly called 7OH, has become one of the most discussed alkaloid compounds in Canadian research circles. Whether you are a laboratory professional refining identification protocols, a researcher studying alkaloid metabolism, or someone trying to understand what 7OH actually is, this guide covers everything you need to know.

We wrote this resource because the existing information about 7OH in Canada tends to be either too surface-level to be useful or too dense for anyone outside of pharmacology. This guide bridges that gap. It explains the chemistry in plain language, breaks down how 7OH differs from its parent compound, walks through laboratory detection methods, and covers the current Canadian regulatory picture as of 2026.

For those looking for calibrated reference materials, you can browse our full catalog of 7OH tablets in Canada at any time.

What Is 7-Hydroxymitragynine (7OH)?

7-Hydroxymitragynine (7OH) is a terpenoid indole alkaloid that originates from the plant Mitragyna speciosa, more commonly known as kratom. Scientists first described this compound in 1994, though research interest has accelerated considerably in the past several years.

At its simplest, 7OH is what you get when the main kratom alkaloid, mitragynine, undergoes oxidation. That oxidation can happen naturally inside the human liver through a process called hepatic metabolism, or it can be carried out in a laboratory through controlled chemical synthesis.

What makes 7OH stand out from other kratom alkaloids is its binding behavior at opioid receptors. Published research has consistently shown that 7OH binds to mu-opioid receptors (MOR) with significantly greater affinity than mitragynine. Multiple studies have measured its MOR binding affinity in the range of 13 to 37 nM, compared to mitragynine’s much weaker binding profile.

But receptor binding only tells part of the story. Unlike conventional opioid compounds, both 7OH and mitragynine appear to act as partial agonists at mu-opioid receptors while functioning as competitive antagonists at delta and kappa-opioid receptors. Researchers have also noted that neither compound appears to activate the beta-arrestin signaling pathway, a distinction that has drawn interest from scientists studying safer analgesic frameworks.

These pharmacological characteristics are why 7OH has attracted serious attention from institutions like the U.S. FDA, the World Health Organization (WHO), and forensic laboratories worldwide.

Where Does 7OH Come From?

Understanding where 7OH comes from helps explain why it is produced the way it is today.

In natural kratom leaves, 7-hydroxymitragynine exists only in trace amounts. Research has consistently shown that it accounts for less than 2% of the total alkaloid content in dried leaf material. The FDA’s own 2025 assessment report confirmed that natural 7OH concentrations in kratom leaf samples ranged from 0.005% to a maximum of 0.21%, with an average of just 0.01%.

Those numbers are important. They mean that extracting meaningful quantities of 7OH directly from kratom leaves is not practical for research or commercial purposes. The yields would be too low and the process too inefficient.

Instead, most 7OH available today is produced semisynthetically. The process starts with mitragynine, which is far more abundant in kratom leaves (typically making up 1 to 2% of dry leaf mass and roughly two-thirds of total alkaloid content). Through controlled oxidation in laboratory settings, mitragynine is converted into 7-hydroxymitragynine.

This semisynthetic production method is the standard across the industry, and it is one reason why sourcing from a supplier that provides verified Certificates of Analysis matters so much. COA documentation confirms the compound’s identity, purity, and the absence of unwanted contaminants.

Chemistry and Molecular Profile

For researchers and laboratory professionals, the specific chemical properties of 7OH are essential for accurate identification and classification. Here is the compound’s core profile:

Property	Value
Chemical Name	7-Hydroxymitragynine
Other Names	7-OH-MIT, 7OHM, 9-methoxycorynantheidine hydroxyindolenine
CAS Number	174418-82-7
Molecular Formula	C₂₃H₃₀N₂O₅
Molecular Weight	414.49 g/mol
Exact Mass	414.2155
Compound Class	Terpenoid indole alkaloid
Source Plant	Mitragyna speciosa (kratom)
First Described	1994 (Ponglux et al.)
Natural Abundance	Less than 2% of total kratom alkaloid content

The compound’s IUPAC name is methyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate.

Structurally, 7OH belongs to the indole alkaloid family. It shares the same core corynanthe-type skeleton as mitragynine. The critical difference is a hydroxyl group (-OH) at the C-7 position, which is the oxidation that converts mitragynine into 7-hydroxymitragynine. This single structural modification increases polarity, changes how the compound behaves during chromatographic separation, and alters its interaction with biological receptors.

How 7OH Is Produced: From Plant to Lab

The production pathway for 7OH follows one of two routes:

Natural formation. In the kratom plant, 7OH forms through spontaneous oxidation of mitragynine. Environmental factors like light exposure, heat, and the age of the plant material can influence the extent of this conversion. In the human body, the liver enzyme CYP3A4 catalyzes the oxidation of mitragynine into 7OH. Research published in ACS Central Science confirmed that this hepatic conversion is a key part of mitragynine’s metabolic pathway, and that 7OH functions as an active metabolite rather than just a byproduct.

Semisynthetic production. Because natural concentrations are too low for practical extraction, laboratory production involves taking purified mitragynine and carrying out controlled oxidation under specific conditions. This approach allows manufacturers to produce 7OH at defined purity levels and consistent concentrations, which is essential for any serious laboratory application.

If you need 7OH for research purposes, we offer a range of research-grade 7OH tablets with batch-specific documentation.

Mitragynine vs 7-Hydroxymitragynine: Key Differences

The comparison between mitragynine and 7-hydroxymitragynine is one of the most common questions in kratom alkaloid research. While the two compounds are closely related, their differences have real implications for laboratory work, detection protocols, and regulatory interpretation.

Property	Mitragynine	7-Hydroxymitragynine
Molecular Formula	C₂₃H₃₀N₂O₄	C₂₃H₃₀N₂O₅
Molecular Weight	398.50 g/mol	414.49 g/mol
Key Functional Group	No C-7 hydroxyl	Hydroxyl group at C-7
Abundance in Kratom	1-2% of dry leaf mass	Less than 0.05% of dry leaf mass
MOR Binding Affinity	~339 nM (EC₅₀)	~34.5 nM (EC₅₀)
Relative Potency	Baseline	Approximately 10x more potent
Polarity	Lower	Higher (due to added -OH group)
HPLC Retention Time	Longer	Shorter (elutes earlier)
Primary Role	Main plant alkaloid	Active metabolite of mitragynine

The difference in polarity is what matters most for laboratory work. That additional hydroxyl group changes how 7OH interacts with chromatographic columns, which means it produces a different retention time during HPLC analysis. For laboratories running identification protocols, this distinction requires separate calibration standards for each compound. You cannot reliably identify 7OH using mitragynine reference standards alone.

The binding affinity difference is also significant. Published data from multiple research groups shows that 7OH has roughly 10 times the potency of mitragynine at mu-opioid receptors (EC₅₀ of approximately 34.5 nM versus 339 nM for mitragynine). This potency difference is central to much of the current regulatory discussion around 7OH products.

For a deeper look at how these compounds are distinguished in the lab, see our guide to 7OH detection methods.

How Laboratories Detect and Analyze 7OH

Accurate identification of 7-hydroxymitragynine depends on validated analytical methods and proper reference standards. Three primary techniques dominate the field.

High-Performance Liquid Chromatography (HPLC) is the most widely used method for 7OH identification and purity assessment. It works by separating compounds based on their interaction with a chromatographic column, then measuring each compound’s retention time against a certified reference standard. For 7OH, HPLC provides reliable identification and quantitative purity data. Most commercial reference standard suppliers, including Cayman Chemical and Santa Cruz Biotechnology, provide HPLC-validated materials for this purpose.

Liquid Chromatography-Mass Spectrometry (LC-MS and LC-QTOF-MS) adds a layer of structural confirmation. After chromatographic separation, mass spectrometry analyzes the compound’s fragmentation pattern. For 7OH, the expected molecular ion appears at m/z 414, with the protonated molecular ion [M+H]⁺ at 415.2227. LC-MS is particularly useful when researchers need to confirm compound identity in complex mixtures or when distinguishing 7OH from structurally similar alkaloids.

Gas Chromatography-Mass Spectrometry (GC-MS) provides an additional verification tool, though researchers should note that some kratom alkaloids can undergo thermal conversion during GC-MS analysis. The Center for Forensic Science Research and Education (CFSRE) has documented this issue specifically with dihydro-7-hydroxymitragynine, which can convert to mitragynine during GC analysis. For this reason, LC-based methods are generally preferred for primary identification.

Nuclear Magnetic Resonance (NMR) spectroscopy can provide definitive structural confirmation and is commonly used during the development of new reference standards. However, NMR requires specialized equipment and larger sample quantities, making it less practical for routine laboratory screening.

For Canadian laboratories establishing or refining their 7OH testing protocols, proper calibration against certified reference standards is essential. Our complete walkthrough of analytical workflows is available in the 7OH detection methods guide.

Is 7OH Legal in Canada?

This is one of the most commonly searched questions about 7OH in Canada, and the answer requires some nuance.

As of 2026, 7-hydroxymitragynine is not listed as a controlled substance under Canada’s Controlled Drugs and Substances Act (CDSA). It does not appear on any of the CDSA schedules. This means that purchasing and possessing 7OH for research purposes is not prohibited by federal controlled substance legislation.

However, Health Canada has not approved any kratom-derived products, including 7OH, for sale as natural health products or for therapeutic use. This is an important distinction. The compound is not banned, but it is also not authorized for human consumption or medical application under Canadian health product regulations.

In practice, this means 7OH products in Canada are sold and purchased specifically for research, laboratory analysis, and other non-therapeutic purposes. Product labeling, intended use statements, and how the product is marketed all matter from a regulatory compliance perspective.

What about the U.S. regulatory situation? The U.S. landscape shifted significantly in 2025. The Department of Health and Human Services (HHS) recommended that 7-hydroxymitragynine be placed in Schedule I of the Controlled Substances Act, and the FDA issued warning letters to vendors marketing concentrated 7OH products. These actions targeted semisynthetic, high-concentration 7OH products rather than natural kratom leaf. As of early 2026, the DEA has not finalized scheduling, but the regulatory momentum in the United States is something Canadian researchers and institutions should monitor, as U.S. policy changes have historically influenced Canadian regulatory discussions.

Important: This guide does not provide legal advice. Canadian regulations can change, and provincial rules may differ from federal ones. Researchers and institutions should consult official sources, including Health Canada and the CDSA schedules, for the most current information.

For answers to common purchasing and compliance questions, visit our FAQ page.

7OH Classification and Regulatory Context

Classification of 7OH varies depending on the jurisdiction and the context in which it is being evaluated.

From a chemical standpoint, 7OH is classified as a terpenoid indole alkaloid. In forensic science contexts, the CFSRE classifies it alongside other novel psychoactive substances (NPS), though this classification reflects analytical cataloging rather than a legal determination.

The WHO Expert Committee on Drug Dependence (ECDD) reviewed kratom, mitragynine, and 7-hydroxymitragynine in a pre-review report. That review documented 7OH’s pharmacological profile, including its receptor binding characteristics and the distinction between natural kratom alkaloid content and semisynthetically produced concentrates.

In Australia, 7-hydroxymitragynine is listed as a Schedule 9 prohibited substance. Several European countries, including Denmark, Poland, and Romania, have banned kratom and its alkaloids entirely. Other jurisdictions are still evaluating how to regulate 7OH specifically, particularly given the emergence of concentrated, semisynthetic products that differ substantially from traditional kratom leaf.

For Canadian researchers, the classification framework that matters most is the CDSA. Since 7OH is not currently scheduled there, the primary regulatory considerations revolve around Health Canada’s natural health product regulations and product marketing compliance.

Research Applications and Laboratory Use

The growing body of research on 7-hydroxymitragynine spans several scientific disciplines. Current laboratory applications include:

Alkaloid metabolism studies. Researchers use 7OH to study how mitragynine is metabolized in the body, particularly the role of the CYP3A4 enzyme in converting mitragynine to its more potent metabolite. Understanding this conversion pathway has implications for drug interaction research and pharmacokinetic modeling.

Receptor binding analysis. Multiple research groups have examined 7OH’s interaction with opioid receptor subtypes. Its profile as a partial mu-agonist that does not recruit beta-arrestin has generated interest among scientists exploring whether compounds with this signaling profile could serve as templates for designing analgesics with improved safety margins.

Reference standard development. As forensic and clinical laboratories expand their testing panels to include kratom alkaloids, the demand for certified 7OH reference materials continues to grow. Laboratories need validated standards to build and maintain accurate calibration curves.

Forensic identification. The CFSRE and other forensic science institutions have begun cataloging 7OH alongside other NPS compounds. Forensic laboratories encountering 7OH in case samples need reliable analytical methods and reference data to produce defensible results.

Structural comparison research. Laboratories compare 7OH to other oxidized and reduced mitragynine derivatives to better understand how structural modifications affect pharmacological activity, stability, and analytical behavior.

For laboratories that need calibrated 7OH materials for any of these applications, our shop carries research-grade tablets across multiple strength tiers. If you are looking for a supplier near your location, our guide on where to find 7OH in Canada covers sourcing considerations in more detail.

Stability, Storage, and Handling

Compound stability is a practical concern for any laboratory working with 7OH. The WHO’s pre-review report on kratom alkaloids noted that 7-hydroxymitragynine is the least stable of the commonly studied kratom compounds, with measurable degradation after 8 hours at 40°C and above.

Best practices for 7OH storage and handling include:

Temperature. Store reference materials at -20°C or below for long-term storage. For short-term use (days to weeks), storage at 0 to 4°C in a dry, dark environment is acceptable. Avoid storing 7OH at room temperature for extended periods.

Light exposure. 7OH is sensitive to light degradation. Store in amber vials or opaque containers, and minimize exposure to direct light during sample preparation.

Moisture. Keep materials sealed and dry. Humidity can accelerate degradation and affect accurate weighing for quantitative analysis.

Solution stability. When preparing 7OH solutions for analysis, use them within the timeframe specified by your laboratory’s validated protocol. Prepared solutions should be stored at reduced temperatures and protected from light.

Reference standard integrity. Always verify the Certificate of Analysis for your specific lot before use. Batch-specific data, including purity percentages and analytical method details, should match your laboratory’s quality requirements.

Why Clear Reporting Matters

One of the less discussed but critically important aspects of 7OH research is the quality of laboratory reporting. When multiple related compounds share similar structures, small analytical errors can cascade into misidentification.

This is especially relevant for forensic laboratories. As the journal Addiction noted in a 2025 paper on semisynthetic 7OH products, forensic laboratories that use mitragynine as a surrogate marker for kratom use risk incorrectly attributing 7OH-related cases to kratom. The presence of trace mitragynine in semisynthetic 7OH products (from incomplete conversion) can create confusion if laboratories do not differentiate between the two compounds in their reporting.

Consistent, transparent reporting requires validated methods, proper reference standards, and clear documentation of what was tested, how it was tested, and what the results mean. These standards benefit everyone involved in 7OH research, from the laboratory analyst to the institution reviewing the data, to the regulatory bodies that rely on accurate scientific reporting to inform policy.

Frequently Asked Questions

What is 7OH?

7OH is the common shorthand for 7-hydroxymitragynine, a terpenoid indole alkaloid derived from the kratom plant (Mitragyna speciosa). It is an oxidized form of mitragynine, the plant’s primary alkaloid. 7OH occurs naturally in trace amounts (less than 2% of total alkaloid content) and is more commonly produced through controlled laboratory oxidation of mitragynine. It has been studied extensively for its mu-opioid receptor binding characteristics.

How is 7OH detected in laboratory analysis?

Laboratories primarily use HPLC to identify 7OH by comparing retention times against certified reference standards. LC-MS provides additional structural confirmation through fragmentation pattern analysis, with the expected molecular ion at m/z 414. GC-MS can serve as a supplementary verification tool, though LC-based methods are preferred because some kratom alkaloids can undergo thermal conversion during gas chromatography. For a full breakdown of analytical workflows, see our 7OH detection methods guide.

What is the difference between mitragynine and 7-hydroxymitragynine?

The primary structural difference is a hydroxyl group at the C-7 position on 7-hydroxymitragynine that is absent from mitragynine. This adds one oxygen atom to the molecular formula (C₂₃H₃₀N₂O₅ vs C₂₃H₃₀N₂O₄) and increases molecular weight from 398.50 to 414.49 g/mol. The added hydroxyl group increases polarity, shifts HPLC retention time, and is associated with approximately 10-fold greater potency at mu-opioid receptors.

Is 7OH legal in Canada?

As of 2026, 7-hydroxymitragynine is not listed as a controlled substance under Canada’s Controlled Drugs and Substances Act. It can be legally purchased and possessed for research purposes. However, Health Canada has not approved 7OH or any kratom-derived product for human consumption or therapeutic use. Regulatory status can change, so institutions should monitor official Canadian sources for updates. For more detail, see our FAQ.

Where can I buy 7OH in Canada?

Research-grade 7OH tablets are available through our online store. We carry multiple strength tiers, and every batch ships with documentation. For information on sourcing near your location, see our guide on buying 7OH in Canada. If you want to find a local source, check out our 7OH near me in Canada resource.

What does a Certificate of Analysis (COA) verify?

A COA documents the results of laboratory testing performed on a specific batch of material. For 7OH, this typically includes compound identity confirmation (usually via HPLC or LC-MS), purity percentage, and testing for contaminants such as heavy metals, pesticides, and microbial content. Reliable COA documentation is essential for any laboratory application.

Disclaimer

The information in this guide is provided for educational and informational purposes only. It is not intended as medical advice and should not be treated as a recommendation for the use, consumption, or application of any product or substance discussed here.

All products sold by 7OH Lab are intended for research and laboratory use only. They are not for human consumption, internal use, or medical applications.

Regulatory information presented in this guide reflects our understanding as of early 2026 and should not be relied upon as legal advice. Researchers and institutions should consult official Canadian regulatory sources for current, jurisdiction-specific guidance.